Nancy Tactuk Romanenko, MD
Internal Medicine · Tuscaloosa, ALNPI 1699923102
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.1% of the total across 1,298 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 44 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,298 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Novo Nordisk$3K
- AstraZeneca$2K
- GSK$2K
- Amgen$1K
- Lilly USA, LLC$1K
- plus $9K from 38 others
What the payments were for
- Speaking & faculty fees$3612%
- Food & beverage$19,73296%
- Education$3742%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$125
- DEXCOM G6 TRANSMITTER$119
How this compares
$20,526 in reported general payments places this provider in the 95th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 339 | $516,232 |
| JardianceEmpagliflozin | 416 | $511,477 |
| MounjaroTirzepatide | 278 | $359,841 |
| EliquisApixaban | 265 | $259,012 |
| RybelsusSemaglutide | 94 | $174,155 |
| FarxigaDapagliflozin Propanediol | 145 | $138,780 |
| Tresiba Flextouch U-200Insulin Degludec | 83 | $99,447 |
| Repatha SureclickEvolocumab | 121 | $95,621 |
| KerendiaFinerenone | 68 | $87,569 |
| TrulicityDulaglutide | 42 | $80,833 |
| LinzessLinaclotide | 57 | $74,779 |
| MyrbetriqMirabegron | 77 | $70,811 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 64 | $60,853 |
| GlyxambiEmpagliflozin/Linagliptin | 69 | $60,244 |
| GemtesaVibegron | 62 | $52,764 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,564 | $690,387433 claims |
| Boehringer IngelheimJardiance, Glyxambi, Synjardy Xr, Trijardy Xr, Tradjenta | $571 | $647,466565 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,175 | $440,674320 claims |
| PfizerEliquis, Premarin | $856 | $277,028305 claims |
| AstraZenecaFarxiga | $1,720 | $138,780145 claims |
| AbbVieLinzess, Ubrelvy, Synthroid | $2,908 | $101,846157 claims |
| BayerKerendia | $630 | $87,56968 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,511 | $87,172107 claims |
| Astellas Pharma US IncMyrbetriq | $645 | $70,81177 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $382 | $52,76462 claims |
| Johnson & JohnsonXarelto | $277 | $49,32836 claims |
| NovartisEntresto | $785 | $37,72938 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Tuscaloosa
- William AlldredgeTuscaloosa$15K
- Ryan WeldonBirmingham$458K
- Thomas McKelveyMobile$365K
- Mary HonkanenMobile$302K
- Robert LewisBirmingham$187K
- Rosalind BowlesGadsden$168K
- Sonja PettusJasper$117K
- Bobby WrightsMobile$89K
- Thomas HuddleBirmingham$76K
- Rahel AzizMobile$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.